Author Archive for Tracy Wolfe
Austin, Texas 07/25/2016 Asuragen, Inc. today announced that it received premarket clearance from the U.S. Food and Drug Administration (FDA) for the QuantideX® qPCR BCR-ABL IS Kit for the monitoring of molecular response in Chronic Myeloid Leukemia (CML) patients. It is the first FDA-cleared diagnostic kit for use in CML management. The kit’s unparalleled sensitivity, reproducibility and simplicity provide clinicians and laboratorians with a unique tool for the robust and accurate assessment of disease clearance in patients, with the potential to help significantly improve the cost and standard of care for patients.
Industry’s First FDA Cleared BCR-ABL Kit has Unprecedented Sensitivity
BURLINGTON, N.C. & SAN DIEGO–(BUSINESS WIRE)–Jul. 27, 2016– Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), the world’s leading healthcare diagnostics company, andSequenom, Inc. (NASDAQ:SQNM), a pioneer in non-invasive prenatal testing (NIPT) for reproductive health, today announced that they have entered into a definitive agreement and plan of merger under which LabCorp would acquire all of the outstanding shares of Sequenom in a cash tender offer for $2.40 per share, or an equity value of $302 million, which represents a total enterprise value of approximately $371 million, including net indebtedness.
Acquisition Creates Market Leader in NIPT, Women’s Health and Reproductive Genetics
PHILADELPHIA–(BUSINESS WIRE)–BioAdvance announced that during the past 12 months it added nine new companies and technologies to its portfolio and made follow-on investments in six of its existing companies. Overall, these investments represent a $2.9M commitment to the success and growth of life science companies and to this region.